Cargando…

Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review

OBJECTIVES: To examine the accessibility and quality of drug company payment data in Europe. DESIGN: Comparative policy review of payment data in countries with different regulatory approaches to disclosure. SETTING: 37 European countries. PARTICIPANTS: European Federation of Pharmaceutical Industri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozieranski, Piotr, Martinon, Luc, Jachiet, Pierre-Alain, Mulinari, Shai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679071/ https://www.ncbi.nlm.nih.gov/pubmed/34916317 http://dx.doi.org/10.1136/bmjopen-2021-053138

Ejemplares similares

Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
por: Mulinari, Shai, et al.
Publicado: (2018)

Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe
por: Ozieranski, Piotr, et al.
Publicado: (2022)

Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)
por: Ozieranski, Piotr, et al.
Publicado: (2020)

Drug company payments to General Practices in England: Cross-sectional and social network analysis
por: Saghy, Eszter, et al.
Publicado: (2021)

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016
por: Stoll, Marlene, et al.
Publicado: (2020)

Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs
por: Mulinari, Shai, et al.
Publicado: (2020)

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
por: Fabbri, Alice, et al.
Publicado: (2018)

Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
por: Pashley, Dylan, et al.
Publicado: (2022)

Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
por: Rickard, Emily, et al.
Publicado: (2023)

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Exposing drug industry funding of UK patient organisations
por: Ozieranski, Piotr, et al.
Publicado: (2019)

Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
por: Stoll, Marlene, et al.
Publicado: (2022)

Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
por: Ozieranski, Piotr, et al.
Publicado: (2019)

National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study
por: Lexchin, Joel, et al.
Publicado: (2022)

Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
por: Robertson, Jane, et al.
Publicado: (2009)

Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study
por: Norris, Susan L, et al.
Publicado: (2012)

Climate Change as a Factor in the Development of Companies: Corporate Strategies and Guidelines for State Industrial Policy
por: Terent’ev, N. E.
Publicado: (2021)

PPARC and European science policy
por: Fletcher, P
Publicado: (2000)

Fundamental Reform of Payment for Adult Primary Care: Comprehensive Payment for Comprehensive Care
por: Goroll, Allan H., et al.
Publicado: (2007)

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

Prescription Drug Payment Policy: Past, Present, and Future
por: Gondek, Kathleen
Publicado: (1994)

Inter-organisational communication networks in healthcare: centralised versus decentralised approaches
por: Pirnejad, Habibollah, et al.
Publicado: (2007)

Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy: European Society of Human Genetics and European Society of Human Reproduction and Embryology
por: Harper, Joyce C, et al.
Publicado: (2013)

Global Budget Payment: Proposing the CAP Framework
por: Chen, Bradley, et al.
Publicado: (2016)

Cancer patients’ organisation participation in heath policy decision-making: a snapshot/cluster analysis of the EU-28 countries
por: Souliotis, Kyriakos, et al.
Publicado: (2018)

Health Policies to Control Chagas Disease Transmission in European Countries
por: Requena-Méndez, Ana, et al.
Publicado: (2014)

Policy parameters for optimising hospital ePrescribing: An exploratory literature review of selected countries of the Organisation for Economic Co-operation and Development
por: Perera, Uditha T, et al.
Publicado: (2022)

Telerehabilitation Policy Report: Interprofessional Policy Principles and Priorities
por: Terrell, Evelyn Abrahante, et al.
Publicado: (2021)

Tourism companies' risk exposures on text disclosure
por: Li, Jianping, et al.
Publicado: (2020)

Organisation der Kernforschung und Atomverwendung
Publicado: (1962)

CERN and ESA: fundamentally contrasting organisations?
por: Bowell, V
Publicado: (1988)

Policy on Ford Foundation
Publicado: (1956)

Policy change and policy dilemmas: interpreting the community services White Paper in England
por: Hudson, Bob
Publicado: (2006)

Impact of US industry payment disclosure laws on payments to surgeons: a natural experiment
por: Rhee, Taeho Greg, et al.
Publicado: (2020)

Professional and governmental policy on community pharmacy: A 10-year policy review and comparative analysis (2008–2017)
por: Paloumpi, Evgenia, et al.
Publicado: (2023)

Error in Payments From Some Pharmaceutical Companies
Publicado: (2019)

Pandemic Action Plan Policy and Regulatory Summary Telehealth Policy and Regulatory Considerations During a Pandemic
por: VanderWerf, Mark, et al.
Publicado: (2022)

European guidelines for constitutional cytogenomic analysis
por: Silva, Marisa, et al.
Publicado: (2018)

How do doctors in the Netherlands perceive the impact of disciplinary procedures and disclosure of disciplinary measures on their professional practice, health and career opportunities? A questionnaire among medical doctors who received a disciplinary measure
por: Laarman, Berber S, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cqck8mh493cvfnfsqlpr4de8ue